S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   437.38 (+0.48%)
AAPL   180.23 (-0.66%)
MSFT   407.94 (+0.05%)
META   486.67 (+0.55%)
GOOGL   136.96 (+0.43%)
AMZN   174.81 (+0.95%)
TSLA   200.00 (-1.01%)
NVDA   791.40 (+1.90%)
NIO   5.64 (+3.87%)
AMD   186.67 (+5.74%)
BABA   74.25 (-0.46%)
T   16.97 (+0.06%)
F   12.39 (+0.73%)
MU   89.65 (-0.07%)
CGC   3.34 (-0.60%)
GE   155.79 (+0.12%)
DIS   111.33 (+0.48%)
AMC   4.41 (-11.62%)
PFE   26.79 (-0.92%)
PYPL   60.26 (+0.02%)
XOM   104.98 (+0.63%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   437.38 (+0.48%)
AAPL   180.23 (-0.66%)
MSFT   407.94 (+0.05%)
META   486.67 (+0.55%)
GOOGL   136.96 (+0.43%)
AMZN   174.81 (+0.95%)
TSLA   200.00 (-1.01%)
NVDA   791.40 (+1.90%)
NIO   5.64 (+3.87%)
AMD   186.67 (+5.74%)
BABA   74.25 (-0.46%)
T   16.97 (+0.06%)
F   12.39 (+0.73%)
MU   89.65 (-0.07%)
CGC   3.34 (-0.60%)
GE   155.79 (+0.12%)
DIS   111.33 (+0.48%)
AMC   4.41 (-11.62%)
PFE   26.79 (-0.92%)
PYPL   60.26 (+0.02%)
XOM   104.98 (+0.63%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   437.38 (+0.48%)
AAPL   180.23 (-0.66%)
MSFT   407.94 (+0.05%)
META   486.67 (+0.55%)
GOOGL   136.96 (+0.43%)
AMZN   174.81 (+0.95%)
TSLA   200.00 (-1.01%)
NVDA   791.40 (+1.90%)
NIO   5.64 (+3.87%)
AMD   186.67 (+5.74%)
BABA   74.25 (-0.46%)
T   16.97 (+0.06%)
F   12.39 (+0.73%)
MU   89.65 (-0.07%)
CGC   3.34 (-0.60%)
GE   155.79 (+0.12%)
DIS   111.33 (+0.48%)
AMC   4.41 (-11.62%)
PFE   26.79 (-0.92%)
PYPL   60.26 (+0.02%)
XOM   104.98 (+0.63%)
S&P 500   5,076.66 (+0.14%)
DOW   38,873.45 (-0.19%)
QQQ   437.38 (+0.48%)
AAPL   180.23 (-0.66%)
MSFT   407.94 (+0.05%)
META   486.67 (+0.55%)
GOOGL   136.96 (+0.43%)
AMZN   174.81 (+0.95%)
TSLA   200.00 (-1.01%)
NVDA   791.40 (+1.90%)
NIO   5.64 (+3.87%)
AMD   186.67 (+5.74%)
BABA   74.25 (-0.46%)
T   16.97 (+0.06%)
F   12.39 (+0.73%)
MU   89.65 (-0.07%)
CGC   3.34 (-0.60%)
GE   155.79 (+0.12%)
DIS   111.33 (+0.48%)
AMC   4.41 (-11.62%)
PFE   26.79 (-0.92%)
PYPL   60.26 (+0.02%)
XOM   104.98 (+0.63%)
NASDAQ:ARCT

Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

$39.26
-0.92 (-2.29%)
(As of 12:03 PM ET)
Today's Range
$39.16
$41.50
50-Day Range
$31.23
$42.99
52-Week Range
$14.21
$43.81
Volume
127,224 shs
Average Volume
371,449 shs
Market Capitalization
$1.05 billion
P/E Ratio
10.88
Dividend Yield
N/A
Price Target
$56.43

Arcturus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.3% Upside
$56.43 Price Target
Short Interest
Bearish
18.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Arcturus Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.38) to ($2.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.81 out of 5 stars

Medical Sector

460th out of 958 stocks

Pharmaceutical Preparations Industry

215th out of 450 stocks


ARCT stock logo

About Arcturus Therapeutics Stock (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

ARCT Stock Price History

ARCT Stock News Headlines

Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
ARCT Jun 2024 22.500 call
ARCT Mar 2024 22.500 call
ARCT Mar 2024 30.000 put
Arcturus Therapeutics Holdings Inc.
Arcturus: H1 2024 Rare Disease Drug Data On Deck
See More Headlines
Receive ARCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/29/2024
Next Earnings (Confirmed)
3/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARCT
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.43
High Stock Price Target
$90.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+40.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$9.35 million
Pretax Margin
34.50%

Debt

Sales & Book Value

Annual Sales
$206 million
Cash Flow
$0.38 per share
Book Value
$10.18 per share

Miscellaneous

Free Float
23,035,000
Market Cap
$1.07 billion
Optionable
Optionable
Beta
2.62
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Joseph E. Payne M.Sc. (Age 52)
    Founder, President, CEO & Director
    Comp: $1.13M
  • Dr. Padmanabh Chivukula (Age 45)
    Founder, Chief Scientific Officer, COO & Secretary
    Comp: $787.5k
  • Mr. Andrew H. Sassine MBA (Age 60)
    CFO & Director
    Comp: $826.88k
  • Mr. Keith C. Kummerfeld CPA
    Senior VP of Finance & Corporate Controller
  • Ms. Neda Safarzadeh
    Vice President and Head of IR/PR & Marketing
  • Mr. Lance Kurata
    Chief Legal Officer
  • Ms. Natash O. Bowman
    Chief Human Resources Officer
  • Mr. Kevin T. Skol
    Chief Business Officer
  • Dr. Juergen Froehlich FCPh (Age 68)
    M.D., MBA, Chief Medical Officer
  • Dr. Igor Smolenov M.D.
    Ph.D., Chief Development Officer














ARCT Stock Analysis - Frequently Asked Questions

Should I buy or sell Arcturus Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARCT shares.
View ARCT analyst ratings
or view top-rated stocks.

What is Arcturus Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for Arcturus Therapeutics' stock. Their ARCT share price targets range from $36.00 to $90.00. On average, they expect the company's share price to reach $56.43 in the next twelve months. This suggests a possible upside of 40.3% from the stock's current price.
View analysts price targets for ARCT
or view top-rated stocks among Wall Street analysts.

How have ARCT shares performed in 2024?

Arcturus Therapeutics' stock was trading at $31.53 at the start of the year. Since then, ARCT shares have increased by 27.6% and is now trading at $40.23.
View the best growth stocks for 2024 here
.

When is Arcturus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our ARCT earnings forecast
.

How can I listen to Arcturus Therapeutics' earnings call?

Arcturus Therapeutics will be holding an earnings conference call on Thursday, March 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.40) by $0.65. The biotechnology company had revenue of $2.44 million for the quarter, compared to the consensus estimate of $26.70 million. Arcturus Therapeutics had a net margin of 33.53% and a trailing twelve-month return on equity of 24.90%. During the same period in the prior year, the business posted ($0.92) EPS.

What is Joe Payne's approval rating as Arcturus Therapeutics' CEO?

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (7.66%), Vanguard Group Inc. (5.46%), Sumitomo Mitsui Trust Holdings Inc. (4.94%), Nikko Asset Management Americas Inc. (4.94%), Dimensional Fund Advisors LP (4.08%) and Granahan Investment Management LLC (1.69%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends
.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARCT) was last updated on 2/29/2024 by MarketBeat.com Staff